Skip to main content
Premium Trial:

Request an Annual Quote

Metabolomic Dx Raises €1.6M to Finish Development of Preeclampsia Test

NEW YORK (GenomeWeb) – Metabolomic Diagnostics today announced that it has raised €1.6 million ($2 million) in venture capital to complete development of PrePsia, a predictive diagnostic test for the early detection of preeclampsia during pregnancy. 

"Securing this new funding will allow Metabolomic Diagnostics to complete PrePsia in our laboratory and assign CE marking to bring the company to first revenues in 2017," CEO Charles Garvey said in a statement. 

The County Cork, Ireland-based company said that the money would also be used to commercialize metabolomic biomarker technology licensed from the Irish Centre for Fetal and Neonatal Translational Research.

Participants in the financing included SOSventures, Enterprise Equity, and Enterprise Ireland, as well as certain private investors. Metabolomic Diagnostics had also raised about €1.5 million in previous private financing rounds.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.